Uflex LtdQ1 FY27
Uflex Ltd Q1 FY27 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Price: ₹630P/E: 6.4Market Cap: ₹4.4K CrSector: Industrial Products
Management growth scorecard
Revenue
Category 2
Margin
Category 3
Fundraise
Yes
Order
N/A
Capex
Yes
2 of 4 growth signals are positive.
Full analysisRevenue guidance
Category 2- →The company expects to double its volume from 173,000+ tonnes in FY26 to FY29, driven by full utilization of new facilities in WPP, Egypt, and India recycling.
- →Top-line growth guidance for FY27 is approximately 30% to 35%, with a similar growth rate expected for FY28.
- →EBITDA and PAT margins are also expected to grow by 30%-35% in FY27, driven by capacity ramp-up and value-added product mix.
- →By FY29, Aseptic plant in Egypt, recycling facility in Noida, and WPP plant are expected to be running at full capacity, supporting sustained growth.
- →CAGR from FY26 to FY29 is estimated around 10%, pending confirmation.
- →Overseas markets are expected to contribute 60%-65% of growth, with India focusing on volume expansion amid competitive pricing.
- →The company aims to maintain sustainable margins and strong operational efficiency over the next three years.
Margin guidance
Category 3- →Q1 FY27 showed strong growth with consolidated revenue up 38% YoY and EBITDA up 92% YoY.
- →For FY27, the company targets a 35% growth in both top line and EBITDA compared to FY26.
- →EBITDA margins reached 15.5% in Q1 FY27, expected to be sustainable or improve, barring geopolitical instability.
- →Overseas operations contribute 60-65% of business with higher margins than India; growth driven significantly by international markets.
- →By FY29, with full capacity utilization of capex projects (Egypt aseptic facility, Noida recycling, WPP bags), expect at least 10% CAGR in top and bottom line.
- →Long-term margin expansion supported by value-added product focus (60-70% of capex).
- →Company plans to reduce debt ratio to 3x by FY28, improving financial health.
- →EPS expected to grow substantially with better tax optimization from overseas margins and operational efficiencies.
Fundraise plans
Yes- →No explicit mention of any new fundraising through debt or equity in the near term.
- →Current focus is on utilizing existing cash flows and capex for growth.
- →Debt reduction is a priority, with leverage expected to reduce from 3.5x to below 3x by FY28.
- →Capex for growth is planned, mostly funded through internal accruals and existing financing.
- →The company is conscious about maintaining a healthy leverage ratio and paying loans and interest on time.
- →No immediate plans for equity dilution or fresh fundraising stated; growth will come from existing investments and expansions.
- →Shareholder rewards primarily through wealth creation via growth rather than buybacks, as the company is in a growth phase.
Order book
The transcript does not provide specific details on the current or expected order book or pending orders for UFlex Limited. However, key relevant insights include:
- The company anticipates robust growth driven by ongoing and upcoming capacity expansions, notably the Egypt aseptic plant with 12 billion pack capacity expected to reach 30% utilization in the current year.
- The company is confident about maintaining strong pricing and margins due to integrated supply chain and diversified geographic presence.
- Demand outlook appears positive with expectations of 35% top-line and EBITDA growth for FY27, supported by volume growth and value-added product mix.
- The management emphasizes a "derisked" business model across geographies to secure supply and demand stability.
- There is no explicit mention of a consolidated order book or pending orders in the disclosed earnings call.
Capex plans
Yes- →Egypt Aseptic Plant: USD 100+ million capex mostly done; remaining capex ~USD 15 million; 12 billion pack capacity; commissioning expected soon; ramp-up target 30% capacity in first year.
- →Dharwad, India: Brownfield BOPP line; USD 10 million done; additional USD 50+ million planned across FY27 and FY28.
- →Mexico Facility: Additional capex ongoing (details not specified).
- →WPP Bags (Noida): USD 54 million capex done; little further capex expected.
- →Total new capex planned ≤ USD 80-100 million for FY27 onward, with 60-70% allocated to high-margin value-added products like Aseptic, WPP bags, and recycling.
- →Capex expected to yield results in 2-3 years, driving sustainable growth through FY29 and beyond.
- →Strategy focuses on geographic diversification and proximity to customers to mitigate geopolitical risks.
Track Uflex Ltd — get its next earnings analysis in your feed
Margin guidance
Category 3- →Q1 FY27 showed strong growth with consolidated revenue up 38% YoY and EBITDA up 92% YoY.
- →For FY27, the company targets a 35% growth in both top line and EBITDA compared to FY26.
- →EBITDA margins reached 15.5% in Q1 FY27, expected to be sustainable or improve, barring geopolitical instability.
- →Overseas operations contribute 60-65% of business with higher margins than India; growth driven significantly by international markets.
- →By FY29, with full capacity utilization of capex projects (Egypt aseptic facility, Noida recycling, WPP bags), expect at least 10% CAGR in top and bottom line.
- →Long-term margin expansion supported by value-added product focus (60-70% of capex).
- →Company plans to reduce debt ratio to 3x by FY28, improving financial health.
- →EPS expected to grow substantially with better tax optimization from overseas margins and operational efficiencies.
Order book
The transcript does not provide specific details on the current or expected order book or pending orders for UFlex Limited. However, key relevant insights include:
- The company anticipates robust growth driven by ongoing and upcoming capacity expansions, notably the Egypt aseptic plant with 12 billion pack capacity expected to reach 30% utilization in the current year.
- The company is confident about maintaining strong pricing and margins due to integrated supply chain and diversified geographic presence.
- Demand outlook appears positive with expectations of 35% top-line and EBITDA growth for FY27, supported by volume growth and value-added product mix.
- The management emphasizes a "derisked" business model across geographies to secure supply and demand stability.
- There is no explicit mention of a consolidated order book or pending orders in the disclosed earnings call.
How does Uflex Ltd rank vs peers in Industrial Products?
Pro feature1Uflex Ltd
Rev 2Mar 3
See full Industrial Products sector rankings
How does Uflex Ltd rank in Industrial Products?
Compare Uflex Ltd against every Industrial Products company (Q1 FY27) on revenue, margins and earnings-call signals.